IL2 and chronic graft versus host disease: In the context of HSCT, preclinical data has shown that IL-2/anti-IL-2 antibody complexes have the capacity to expand Tregs and ameliorate chronic GVHD, a low inflammatory disease, while aggravating acute GVHD, a high inflammatory disease [49].